Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors

  • Bioorg Med Chem Lett. 2019 Sep 15;29(18):2638-2645. doi: 10.1016/j.bmcl.2019.07.045.
Baolei Wang  1 Xuehong Chen  2 Jianjun Gao  3 Li Su  1 Li Zhang  1 Hongwei Xu  2 Yepeng Luan  4
Affiliations
  • 1. Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
  • 2. Department of Pharmacology, College of Basic Medicine, Qingdao University, Qingdao, Shandong, China.
  • 3. Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
  • 4. Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, Shandong, China. Electronic address: [email protected].
Abstract

Histone deacetylases (HDACs) have proven to be promising targets for the development of anti-cancer drugs. In this study, we reported a series of novel chalcone based tubulin and HDAC dual-targeting inhibitors. Three compounds inhibited the activities of HDAC and tubulin polymerization simultaneously and displayed anti-proliferative activities toward eleven human tumor cell lines. Compound 8a remarkably induced growth inhibition, Apoptosis and G2/M phase arrest of A549 tumor cells. Finally, the inhibitory activities of 8a against HDAC6 and tubulin were rationalized by molecular docking studies.

Keywords
Antitumor; Chalcone; Dual-targeting; Histone deacetylase; Inhibitor; Tubulin polymerization.